Geoffrey Jones
Interventional Pain Medicine · Tampa, FLNPI 1952515678
Payments from drug & device makers
Across 223 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$806
- Collegium Pharmaceutical, Inc.$505
- Scilex Pharmaceuticals Inc.$477
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$390
- Lilly USA, LLC$340
- Boston Scientific$249
- plus $2K from 31 others
What the payments were for
- Travel & lodging$75616%
- Food & beverage$3,89284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 4 | $806 |
| Collegium Pharmaceutical, Inc. | 29 | $505 |
| Scilex Pharmaceuticals Inc. | 29 | $477 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $390 |
| Lilly USA, LLC | 20 | $340 |
| Boston Scientific | 20 | $249 |
| Biohaven Pharmaceuticals, Inc. | 8 | $242 |
| IBSA Pharma Inc. | 12 | $225 |
| Daiichi Sankyo Inc. | 7 | $180 |
| Amgen(2 entities) | 10 | $174 |
| Pfizer | 7 | $126 |
| AbbVie(2 entities) | 7 | $113 |
| Spinal Simplicity, LLC | 3 | $112 |
| Protega Pharmaceutials Inc | 5 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $76 |
| Teva Pharmaceuticals USA, Inc. | 5 | $72 |
| Curonix LLC | 2 | $38 |
| Fidia Pharma USA Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Tersera Therapeutics LLC | 2 | $27 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Shionogi Inc | 2 | $25 |
| Stratus Medical, LLC | 2 | $25 |
| Novo Nordisk | 1 | $23 |
| MVP Orthopedics Inc | 1 | $22 |
| Angiodynamics, Inc. | 1 | $22 |
| Vertex | 1 | $22 |
| Forte Bio-pharma LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| SPR Therapeutics, Inc | 1 | $20 |
| Medela LLC | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Piramal Critical Care | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IFUSE IMPLANT SYSTEM$720
- NURTEC ODT$125
- Morphabond ER$117
How this compares
$4,648 in reported general payments places this provider in the 45th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 15 | $32,106 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,004 | $30,466 |
| BelbucaBuprenorphine Hcl | 26 | $22,336 |
| Xtampza ErOxycodone Myristate | 30 | $19,701 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 717 | $18,158 |
| Lidocaine | 115 | $9,443 |
| Oxycodone Hcl | 528 | $8,231 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 141 | $7,452 |
| OxycontinOxycodone Hcl | 16 | $7,142 |
| Gabapentin | 550 | $7,128 |
| Buprenorphine | 17 | $6,428 |
| Pregabalin | 324 | $6,176 |
| Morphine Sulfate ErMorphine Sulfate | 227 | $5,102 |
| Tizanidine Hcl | 496 | $4,937 |
| MovantikNaloxegol Oxalate | 12 | $4,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $505 | $42,03756 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $390 | $32,10615 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $27 | $7,23750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Tampa
- Neil EllisTampa$1.1M
- Jose RiveraTampa$993K
- Ajay AntonyGainesville$1.9M
- Louis RasoJupiter$1.6M
- Gilbert MbeoOrlando$1.4M
- George BesongOrange City$1.2M
- Gary KaoMiddleburg$1.1M
- Alexis RentaBoynton Beach$1.1M
- Michael EspositoVero Beach$1M
- Nomen AzeemRiverview$691K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.